Disruptive Behavior Disorder Treatment Market – By Disorder Type, By Treatment Type, By End Use – Global Forecast 2025 – 2034

Disruptive Behavior Disorder Treatment Market Size

The global disruptive behavior disorder treatment market size was valued at USD 1.5 billion in 2024 and is estimated to grow at 5.4% CAGR from 2025 to 2034. Disruptive behavior disorder treatment includes the management of disorders such as oppositional defiant disorder, conduct disorder, and intermittent explosive disorder.
 

Treatment includes both medical approaches and behavioral modification. The objectives of these therapies are to lessen the symptoms, enhance emotional and social functioning, and avert further deterioration. Behavioral disorder cases such as attention-deficit hyperactivity disorder (ADHD) are on the rise globally resulting in growth in the treatment market for disruptive behavior disorders. For instance, data collected in a national parent survey in 2022 by Centers for Disease Control and Prevention (CDC) which claims around 7 million (11.4%) of children between 3-17 years in the U.S have received an ADHD diagnosis. Children who have been diagnosed with ADHD are at higher risk of developing a behavioral disorder as ADHD often co-exists with behavioral disorders.
 

Furthermore, the increase in the prevalence of behavioral disorders can be attributed to the growing awareness of mental health in addition to better diagnostic systems and increasing societal pressures. The higher numbers underline the greater magnitude of need to put in place a mechanism that helps in managing the symptoms, behavioral outcomes, and life quality of life.
 

Furthermore, the expansion of the treatment of behavioral disorders is aided by improvements made in digital therapeutics which have enhanced the provision of personalized health care. Many efforts have already been made with the use of mobile health apps, telepsychiatry platforms, and AI tools including digital cognitive behavioral therapy (CBT) programs and therapy apps targeted to children and adolescents. For instance, Akili Interactive’s EndeavorRx, the first video game marketed for the treatment of ADHD, which was compelling enough for the children to play.
 

The company received initial U.S. FDA approval in June 2020. Further, it introduced new features in March 2021 and in March 2024, it has received clearance from the U.S. FDA an over-the-counter treatment for adults with ADHD. Such technologies are making it possible to improve the treatment and motivate key players to further invest in the area increasing the growth of the industry.
 

Disruptive Behavior Disorder Treatment Market Trends

• The emphasis on understanding disruptive behavior disorders and their early diagnosis is helping to develop the market. The awareness is driven by campaigns on mental health, educational aids, and healthcare organization efforts aimed at discrimination reduction regarding behavioral disorders.
   
• For instance, the ADHD Awareness Month organized each October by CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) assists in raising awareness of the condition and its treatment. These initiatives aid in the early identification of cases and provision of care within an appropriate timeframe and hence contribute to the increased use of therapeutic measures.
   
• Additionally, government initiatives are, for instance, supporting telepsychiatry, which is projected to reach USD 39.9 billion by 2032, and other digital mental health tools. These provide the ability to pay for services and allow for the rapid implementation of new methods into traditional treatment of DBDs.
   
• Thus, early diagnosis and integrated treatment are promoted by aforementioned measures, which facilitates market growth through increased implementation of therapeutic measures.
   

Disruptive Behavior Disorder Treatment Market Analysis

Based on disorder type, the market is segmented into oppositional defiant disorder, conduct disorder and intermittent explosive disorder. The market was valued at USD 1.44 billion in 2023. The conduct disorder segment held leading position in the market, accounting for USD 1 billion in 2024.
 

• Conduct Disorder (CD) involves patterns of aggressive, antisocial, and disruptive behavior, usually found among children and adolescents. Its severity and high treatment demand with pharmacological and behavior corrective measures drives this segment.
   
• For instance, data from the National Institutes of Health suggests that conduct disorders are prevalent in 2-4% of children and adolescents worldwide, and its proactive outpatient psychological intervention has resolved more than two-thirds of the recorded cases which indicates the importance of early management of the condition.
   
• Moreover, market growth has been accelerated by increasing awareness on the need for effective interventions such as antipsychotic medicines and cognitive-behavioral therapy.

Based on treatment type, the disruptive behavior disorder treatment market is segmented into drugs and therapy. The drugs segment is further subdivided into antipsychotics, stimulants, non-stimulant ADHD medications, and other drugs. Further, therapy segment is bifurcated into comprehensive evaluation, family therapy, parenting modification, group therapy, individual therapy, and social and emotional skills training. The therapy segment emerged as a dominant segment in the market, accounting for 59.4% of revenue share in 2024 and is expected to reach by USD 1.5 billion in 2034.
 

• The therapy element in the management of disruptive behavior disorders encompasses parent therapy, family therapy, social-emotional skills training, etc., usually offered by a mental health clinician.
   
• Furthermore, therapy or counseling is especially important in resolving underlying behavioral issues, which is why it is important for the management of behavioral disorders. For instance, according to National Library of Medicine, parent management training (PMT) is recommended treatment for children up to 12 years of age with disruptive behavior disorders.
   
• The anticipated increase in the need for competent and non-invasive means of treatment will strengthen growth further in this segment of the market.
   

Based on end use, the disruptive behavior disorder treatment market is segmented into hospitals, psychiatric clinics, rehabilitation centers and other end users. Hospitals accounted for the largest revenue share of 44.7% in 2024.
 

• In the treatment of disruptive behavior disorders, hospitals play an important role for patients with more severe cases that need dedicated and intensive treatment. These institutions provide full service that includes inpatient care, evaluation, support by multidisciplinary teams, and the creation of a tailored treatment plan.
   
• In addition, such patients who have complex or urgent problems are likely to be met properly as hospitals have the required psychiatric, constant observation, and emergency resources. For this reason, hospitals are the major factor in the growth of the market of DBD treatment for both immediate and long-term care.
   
• Given the ability for inpatient care, elaborate diagnostics, and support from a multi-disciplinary team, hospitals have been noted to play a significant role in the management of severe disruptive behavior disorders.
   

North America: The disruptive behavior disorder treatment market in the U.S. is expected to grow significantly, from USD 580.7 million in 2023 to reach USD 1 billion by 2034.
 

• The country has an increasing number of people diagnosed with the disorder. According to CDC, in 2022, approximately 7 million children, between the ages of three and seventeen were diagnosed with ADHD. In addition, approximately 3.3% of children suffer from oppositional defiant disorder (ODD).
   
• The country’s strong focus on healthcare innovation has fostered the development of advanced treatments, which has significantly contributed to an expanding market.
   

Europe: The disruptive behavior disorder treatment market in the UK is projected to experience steady growth between 2025 and 2034.
 

• The National Health Service (NHS) in the UK does a commendable job in making treatment options for disruptive behavior disorders (DBD) affordable and available. The NHS offers therapies through government-funded mental health schemes which subsidize the costs of generic drugs and basic behavioral therapy, enabling greater market access.
   
• Increase in patients and health personnel being knowledgeable of DBD has resulted to a higher number of people being diagnosed and an increased need for effective treatment. National Institute of Health assert that about 5% of children are diagnosed with conduct disorder (CD) while the numbers of ADHD reach at 3-5%.
   
• In response to the escalating demand for mental health assistance, the NHS has greatly increased its spending on Child and Adolescent Mental Health Services (CAMHS) by USD 2.9 billion as part of the NHS Long Term Plan. The funding seeks to bolster the mental healthcare system by improving early intervention, increasing the accessibility of therapies, and supporting industry growth.
   

Asia Pacific: Japan disruptive behavior disorder treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan has seen an increase in the recognition of attention-deficit hyperactivity disorder and other neurodevelopmental disorders from healthcare professionals, educators, and even parents. Consequently, more children are undergoing evaluations which directly leads to higher rates of diagnosis.
   
• Moreover, telepsychiatry and digital therapeutics is becoming increasingly widespread for the treatment of DBDs in Japan.
   
• Japan also benefits from strong healthcare structure which helps in country's rapid expansion in the market for treatment of disruptive behavior disorders.
   

Middle East and Africa: The disruptive behavior disorder treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The Government of Saudi Arabia is directing its endeavors towards enhancement of mental health services as set in the countries Vision 2030 strategy while spending considerable amount on healthcare systems and enabling treatment of mental and behavioral health disorders.
   
• Further, the rise in the prevalence of disruptive behavior disorders in Saudi Arabia, especially in children and adolescents, can be attributed to the improved awareness and better capabilities of diagnosing these disorders.
   
• For instance, the Saudi Arabia Country Report 2023 states that adolescents aged 15-22 diagnosed with some form of disruptive behavior disorder were 15.44%.
   

Disruptive Behavior Disorder Treatment Market Share

The market is highly competitive, with pharmaceutical companies, therapy providers, and digital health innovators vying for market share. Top 4 players in the market include Eli Lilly, Pfizer, Novartis and Johnson & Johnson. These account for around 40% of the market share. Key players are focusing on developing advanced therapies, such as precision medicine and digital behavioral therapy platforms, to meet patient needs. The use of telepsychiatry integrated with AI diagnostic tools greatly advanced the early diagnosis and treatment accessibility, which raises the competition bar.
 

The presence of competitively priced generic drugs makes it easier for the private and public healthcare systems to shift their focus towards effective purchasing strategies. The industry has also seen numerous strategic partnerships and consolidation with both private and public psychiatric clinics, hospitals, and medical rehabilitation services providers to increase their market reach. Initiatives to support telehealth and the rapid approval of new treatment innovations are few policies that create advantages for businesses. These policies aim to respond to the demand for affordable, comprehensive services which, in turn, reinforces the status of top industry players.
 

Disruptive Behavior Disorder Treatment Market Companies

Some of the eminent market participants operating in the disruptive behavior disorder treatment industry include:

• Drugs:
  • Bionomics
  • Eli Lilly and Company
  • Johnson & Johnson
  • Mylan
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Tris Pharma
• Therapy:
  • Boston Children's Hospital
  • Highland Ridge Hospital
  • INTEGRIS Health
  • Lakeview Health
  • Springwoods Behavioral Health
     

• Boston Children's Hospital is one of the leading pediatric hospitals with a dedicated psychiatry and behavioral health division. The hospitals offers treatment for children with disruptive behavior disorders. The hospital integrates cognitive-behavioral therapy (CBT), parent management training (PMT), and pharmacological interventions to provide a holistic approach to treatment.
   
• Pfizer is a key player in the market and is globally present. It is operating in more than 180 countries worldwide.
   

Disruptive Behavior Disorder Treatment Industry News:

• In November 2023, Tris Pharma, a biopharmaceutical company specializing in ADHD, pain, addiction and neurological disorders, announced the approval of Quillivant XR (extended-release methylphenidate HCl oral suspension) and QuilliChew ER (extended-release methylphenidate HCl chewable tablets) for ADHD treatment in additional international markets. The approval in additional international markets is expected to strengthen the company’s position in the broader neurodevelopmental disorder treatment space, including disruptive behavior disorders (DBD).
   

The disruptive behavior disorder treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disorder Type

• Oppositional defiant disorder
• Conduct disorder
• Intermittent explosive disorder

Market, By Treatment Type

• Drugs
  • Antipsychotics
  • Stimulants
  • Non-stimulant ADHD medications
  • Other drugs
• Therapy
  • Comprehensive evaluation
  • Family therapy
  • Parenting modification
  • Group therapy
  • Individual therapy
  • Social and emotional skills training

Market, By End Use

• Hospitals
• Psychiatric clinics
• Rehabilitation centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE